AI English summary of an SEC filing — figures as filed
Revvity RVTYThe company said revenue for Q3 2024 was $684 million, compared with $671 million a year earlier, and GAAP operating income from continuing operations was $98 million, compared with $69 million a year earlier. GAAP operating profit margin was 14.3%, compared with 10.3% a year earlier.
Key points
AI summaryThe company said revenue for Q3 2024 was $684 million, compared with $671 million a year earlier, and GAAP operating income from continuing operations was $98 million, compared with $69 million a year earlier. GAAP operating profit margin was 14.3%, compared with 10.3% a year earlier.
Revvity said Life Sciences revenue for Q3 was $301 million (organic revenue down 3%), and adjusted operating profit margin was 34.2% (37.1% a year earlier). Diagnostics revenue was $383 million (organic revenue up 5%), and adjusted operating profit margin was 26.5% (22.5% a year earlier).
Revvity updated its full-year revenue guidance to $2.75 to $2.77 billion, assuming organic growth of 0% to 1%, and raised its adjusted EPS guidance to a range of $4.83 to $4.87. The company also said its board approved a new 2-year share repurchase program of $1 billion, which replaces the remainder of the existing program.
The company said operating cash flow from continuing operations for the 9 months ended 2024 was $489,488 thousand. In Q3, it paid $711,479 thousand to redeem senior unsecured notes, and proceeds from U.S. Treasury Securities were $710,000 thousand.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q3 2024 Revenue and Operating Income
The company said revenue for Q3 2024 was $684 million, compared with $671 million a year earlier, and GAAP operating income from continuing operations was $98 million, compared with $69 million a year earlier. GAAP operating profit margin was 14.3%, compared with 10.3% a year earlier.
Source · Based on the filing body and exhibits
Life Sciences and Diagnostics Segment Revenue and Adjusted Operating Margin for Q3
Revvity said Life Sciences revenue for Q3 was $301 million (organic revenue down 3%), and adjusted operating profit margin was 34.2% (37.1% a year earlier). Diagnostics revenue was $383 million (organic revenue up 5%), and adjusted operating profit margin was 26.5% (22.5% a year earlier).
Source · Based on the filing body and exhibits
Full-Year Outlook and New Share Repurchase Program
Revvity updated its full-year revenue guidance to $2.75 to $2.77 billion, assuming organic growth of 0% to 1%, and raised its adjusted EPS guidance to a range of $4.83 to $4.87. The company also said its board approved a new 2-year share repurchase program of $1 billion, which replaces the remainder of the existing program.
Source · Based on the filing body and exhibits
9-Month Cash Flow and Q3 Debt Redemption
The company said operating cash flow from continuing operations for the 9 months ended 2024 was $489,488 thousand. In Q3, it paid $711,479 thousand to redeem senior unsecured notes, and proceeds from U.S. Treasury Securities were $710,000 thousand.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…